When to Conduct Hepatic Impairment Studies and When Modeling May be Enough
How to decide if a hepatic impairment study is required, choose the right study design,…
Certara2026年7月13日
Dosimetry tells you the dose. It doesn’t tell you the decision.
Learn why absorbed dose data alone isn't enough for radiopharmaceutical dose optimization, and how BED,…
Certara2026年7月7日
Enhancing clinical trials with real-world evidence in pregnancy research
Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…
Certara2026年6月26日
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development
Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…
Danielle Pillsbury2026年6月23日
Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…
Certara2026年6月23日
Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study
Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…
Certara2026年6月23日
